Having outgrown th SBIR program, Spectranetics has not been Program involved in many years. Inlate June 2017 it was announced that Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and The Spectranetics Corporation (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions, had entered into a definitive merger agreement. The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system, in conjunction with its proprietary excimer laser system. Excimer laser technology delivers comparatively cool ultraviolet energy in short, controlled energy pulses to ablate or remove tissue. The Company's excimer laser system includes the CVX-300 laser unit and various fiber-optic delivery devices, including disposable catheters and sheaths. Its excimer laser system is approved in both the United States and Europe for use in multiple, minimally invasive cardiovascular applications. Its excimer laser system is used in complex atherectomy procedures to open clogged or obstructed arteries in the coronary vascular system. It is also used to remove lead wires from patients with implanted pacemakers or cardioverter defibrillators, which are electronic devices that regulate the heartbeat.
